Dyadic (DYAI) and Scripps Research Collaborate on Hantavirus Antibody and Vaccine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. IQMX
4. EROC
5. SPY
6. MSTR
7. SEER
8. FRBT
9. MSFT
10. USO

Go back to Dyadic (DYAI) and Scripps Research Collaborate on Hantavirus Antibody and Vaccine

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

May 28, 2026 7:25 AM EDT

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadics C1 Platform Capabilities for Fast, Scalable Biologic Production

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Dyadic, we, us, our, or the Company) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus... More